Aminohippurate Sodium

(Para-aminohippurate)

ApprovedSmall molecule

Merck & Co.

Aminohippurate Sodium is one of 85 small molecule programs targeting Acute Kidney Injury. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Acute Kidney InjuryActive, not recruiting

Heart FailureCompleted

Acute Kidney InjuryPreclinical

Active, not recruiting

Heart FailureApproved

Completed

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

Aminohippurate Sodium

Merck & Co.

Approved

1 2

Bayer Aspirin

Bayer

Preclinical

2 3

Brethine

Sanofi

Preclinical

1 4

Medrol

Pfizer

Preclinical

1 5

Amidate

Pfizer

Preclinical

1 6

Zemplar

Adriamycin

Savaysa

Activase

Xifaxan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Acute Kidney Injury

NCT05694624

Clinical

Trials by Indication[1]

Phase 11 trial

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

Completed· GSK logo

GSK·Phase 1·NCT01214993·38 enrolled

ARB1 trial

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

Completed·YYale University·Phase 4·NCT04649229·46 enrolled

Acute Kidney Injury1 trial

Investigations Into Sepsis-associated Acute Kidney Injury

Recruiting·UUniversity Hospital of North Norway··NCT05694624·20 enrolled

Heart Failure1 trial

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

Completed·VVanderbilt University Medical Center·Approved·NCT04113109·46 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

AMINOHIPPURATE SODIUM

NDA NDA005619

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Para-aminohippurate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Para-aminohippurate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Para-aminohippurate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA005619). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Merck & Co.

Aminohippurate Sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Phase 11 trial

ARB1 trial

Acute Kidney Injury1 trial

Heart Failure1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News